• Menopause Tracking Tools
• Log In
• Register

• Home
• 35 Symptoms
• Beauty
• BHRT
• Health & Fitness
• Hot Flash!
• News
• Reviews
• Supplements

• About
• Contact
• Menopause Tracking Tools

• Subscribe

Combined HRT use over 10 years can increase lung cancer risk

By Hot Flash

Reuters report on a study that finds that long term use of combined estrogen+progestin HRT can increase your risk of lung cancer. The study published in the Journal of Clinical Oncology found estrogen only usage had no increase in risk nor did combined usage under 10 years.

Tweet This

This entry was posted on Wednesday, February 24th, 2010 at 3:01 pm and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

One Response to “Combined HRT use over 10 years can increase lung cancer risk”

1. Hot Flash

   5 March, 2010 at 11:41 am

   The study abstract can be read here

   It says:

   Purpose: Lung cancer is the leading cause of cancer-related mortality among women. The role of hormone replacement therapy (HRT) in lung cancer development is unclear.

   Patients and Methods: We evaluated a prospective cohort of 36,588 peri- and postmenopausal women aged 50 to 76 years from Washington State recruited in 2000 to 2002 (Vitamins and Lifestyle [VITAL] Study). Lung cancer cases (n = 344) were identified through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results cancer registry during 6 years of follow-up. Hazard ratios (HRs) associated with use and duration of specific HRT formulations were calculated for total incident lung cancer, specific morphologies, and cancer by stage at diagnosis.

   Results: After adjusting for smoking, age, and other potential confounders, there was an increased risk of incident lung cancer associated with increasing duration of estrogen plus progestin (E+P) use (HR = 1.27 for E+P use 1 to 9 years, 95% CI, 0.91 to 1.78; and HR = 1.48 for E+P use 10 years, 95% CI, 1.03 to 2.12; P for trend = .03). There was no association with duration of unopposed estrogen use. Duration of E+P use was associated with an advanced stage at diagnosis (P for trend = .03).

   Conclusion: Use of E+P increased the risk of incident lung cancer in a duration-dependent manner, with an approximate 50% increased risk for use of 10 years or longer. These findings may be helpful for informing women of their risk of developing lung cancer and delineating important pathways involved in hormone metabolism and lung cancer

   .

   #296